Jazz Pharmaceuticals PLC

JAZZ

Equity

ISIN IE00B4Q5ZN47 / Valor 14769757

NASDAQ (2026-10-08)

USD 222.45-3.78%

Jazz Pharmaceuticals PLC
UMushroom community rating:

4.00 3 votes No rating yet

NegativeNeutralPositive

About company

Jazz Pharmaceuticals PLC is a biopharmaceutical company known for its focus on developing and commercializing innovative medicines aimed at addressing significant unmet medical needs. With a strong presence on the NASDAQ (JAZZ), the company has carved out a niche in the healthcare sector, particularly in the areas of sleep disorders, epilepsy, and oncology. Jazz Pharmaceuticals boasts a diverse portfolio of marketed medicines, with leading therapies that have made substantial impacts in their respective fields. The company's commitment to patient-focused and science-driven initiatives is evident in its robust pipeline, which is dedicated to pioneering research and development in oncology and neuroscience. Through its efforts, Jazz Pharmaceuticals aims to transform the lives of patients and their families by offering new, advanced therapeutic options.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

61.5%1Y

72.5%3Y

63.6%5Y

Performance

35.7%1Y

33.3%3Y

31.3%5Y

Volatility

14440 M

Market cap (USD)

1,268,631

Daily traded volume (Shares)

124.03 / 122.1

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.00

3 votes

Performance:

4.00

Innovation:

4.67

Society:

4.33

Nature:

4.00

Eric Strauss

Switzerland, 12 Feb 2025

Könnte mit den Anlaufenenden Patenten, wirklich vielversprechend sein!

Admin UMushroom

Switzerland, 12 Feb 2025

Luba Schoenig

Switzerland, 12 Feb 2025

Jazz Pharmaceuticals reported a 14% year-over-year revenue increase in Q3 2024, driven by strong performance from Xywav, Epidiolex, and Rylaze. The company reaffirmed its 2024 total revenue guidance of 4.0-4.1 billion, supported by robust patient demand for Xywav (+17% sales growth) and Epidiolex’s

EQUITIES OF THE SAME SECTOR

Haemonetics Corp